Cover Image

Initial experience with transcatheter tricuspid valve repair in patients with cardiac amyloidosis

Aims Wildtype transthyretin amyloid cardiomyopathy is an under-recognized cause of heart failure in elderly patients. Transcatheter tricuspid valve repair is a newly emerging therapeutic option for severe tricuspid regurgitation (TR). We present first insights into safety and possible benefits of th...

Full description

Saved in:
Bibliographic Details
Main Authors: Hörbrand, Isabel (Author) , Volz, Martin J. (Author) , Siepen, Fabian aus dem (Author) , Aurich, Matthias (Author) , Schlegel, Philipp (Author) , Geis, Nicolas (Author) , Hegenbart, Ute (Author) , Konstandin, Mathias (Author) , Frey, Norbert (Author) , Raake, Philip (Author)
Format: Article (Journal)
Language:English
Published: April 2023
In: ESC heart failure
Year: 2023, Volume: 10, Issue: 2, Pages: 1003-1012
ISSN:2055-5822
DOI:10.1002/ehf2.14262
Online Access:Resolving-System, kostenfrei, Volltext: https://doi.org/10.1002/ehf2.14262
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ehf2.14262
Get full text
Author Notes:Isabel A. Hoerbrand, Martin J. Volz, Fabian Aus dem Siepen, Matthias Aurich, Philipp Schlegel, Nicolas A. Geis, Ute Hegenbart, Mathias H. Konstandin, Norbert Frey and Philip W. Raake
Description
Summary:Aims Wildtype transthyretin amyloid cardiomyopathy is an under-recognized cause of heart failure in elderly patients. Transcatheter tricuspid valve repair is a newly emerging therapeutic option for severe tricuspid regurgitation (TR). We present first insights into safety and possible benefits of this procedure in patients with cardiac amyloidosis. Methods and results Eight patients with cardiac non-hereditary (wildtype) transthyretin (ATTRwt) amyloidosis and severe to torrential TR, undergoing successful transcatheter tricuspid valve repair, were included in the analysis and compared to a control group of 21 patients without cardiac amyloidosis. All patients presented with an advanced stage of amyloid cardiomyopathy. Primary endpoint was reduction in TR at 3 months follow-up. Secondary endpoints were feasibility, safety, hospitalization or death, clinical improvement, cardiac biomarkers, and structural and functional right heart parameter obtained by echocardiography. Transcatheter tricuspid valve repair resulted in a significant reduction of TR (IV to II, P = 0.008) in all eight patients with cardiac amyloidosis (100%). Device success (amyloidosis 75% vs. control group 86%, P = 0.597) and overall probability of hospitalization or death (amyloidosis 13% vs. control group 25%, P = 0.646) were similar compared with those in the control group at 3 months follow-up. Transcatheter tricuspid valve repair led to an improvement of New York Heart Association functional class (P = 0.031) and 6 min walking distance (from 313 ± 118 to 337 ± 106, P = 0.012). TR reduction in amyloidosis patients was less extensive compared with that in control group (TR-reduction 1.6 ± 0.3, P = 0.008 vs. control group 2.3 ± 0.3, P < 0.0001). Furthermore, these patients showed no significant improvement of structural right heart parameters. Conclusions Transcatheter tricuspid valve repair is a safe and feasible new treatment option in patients with amyloid cardiomyopathy and has the potential to improve TR-grade and clinical status. However, the benefit appears to be less pronounced compared with patients without cardiac amyloidosis.
Item Description:Online veröffentlicht: 13. Dezember 2022
Gesehen am 22.08.2024
Physical Description:Online Resource
ISSN:2055-5822
DOI:10.1002/ehf2.14262

Similar Items